| Philip Frederick Rellihan Jr, RPH | |
|
11131 W 79th St, Lenexa, KS 66214 | |
| (816) 234-4664 | |
| (913) 234-4665 |
| Full Name | Philip Frederick Rellihan Jr |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 11131 W 79th St, Lenexa, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811109697 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-11294 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Philip Frederick Rellihan Jr, RPH 18605 E 25th Terr Crt S, Independence, MO 64057 Ph: (816) 795-6321 | Philip Frederick Rellihan Jr, RPH 11131 W 79th St, Lenexa, KS 66214 Ph: (816) 234-4664 |
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).
Jack Griffin, an internationally acclaimed and admired expert on diseases of the peripheral nervous system, founding director of the Johns Hopkins Brain Science Institute, and former director of Hopkins School of Medicine's Department of Neurology, died Saturday, April 16, after a long battle with bladder cancer. He was 69.
A Duke University study is the first to link specific differences in brain structure to what is common across many types of mental illness.
In the largest collaborative study of the brain to date, researchers from the Keck School of Medicine of the University of Southern California led a global consortium of 190 institutions to identify eight common genetic mutations that appear to age the brain an average of three years. The discovery could lead to targeted therapies and interventions for Alzheimer's disease, autism and other neurological conditions.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
› Verified 8 days ago
Jacob Thomas Stolz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15100 W 87th Street Pkwy, Lenexa, KS 66219 Phone: 913-438-5172 | |
Katy Dolinar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13400 W 87th Street Pkwy, Lenexa, KS 66215 Phone: 913-438-6651 | |
Christopher Shane Slifer, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11131 W 79th St, Lenexa, KS 66214 Phone: 913-234-4664 Fax: 913-234-4665 | |
Jill Ann Ottinger, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11131 W 79th St, Lenexa, KS 66214 Phone: 913-234-4664 | |
Jerald E. Bowmer, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 17301 W 84th Ter, Lenexa, KS 66219 Phone: 913-530-1493 Fax: 913-599-5435 | |
Ms. Elaine Carol Clancy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11162 Renner Blvd, Lenexa, KS 66219 Phone: 800-360-0520 | |
Jonathan Fernandez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10050 Woodland Dr, Lenexa, KS 66220 Phone: 913-397-0906 Fax: 913-397-0332 |